This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shammas, M. A. Articles by Munshi, N. C. Search for Related Content PubMed PubMed Citation Articles by Shammas, M. A. Articles by Munshi, N. C.

Telomerase Inhibition and Cell Growth Arrest After Telomestatin Treatment in Multiple Myeloma

¹ Boston VA Health Care System, Boston, Massachusetts; ² Dana Farber Cancer Institute, Boston, Massachusetts; ³ Harvard Medical School, Boston, Massachusetts; ⁴ Departments of Geriatrics, and Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, and Central Arkansas Veterans Health Care System, Little Rock, Arkansas; and ⁵ Arizona Cancer Center and College of Pharmacy, University of Arizona, Tucson, Arizona

Purpose: The aim of this study was to test the efficacy of telomestatin, an intramolecular G-quadruplex intercalating drug with specificity for telomeric sequences, as a potential therapeutic agent for multiple myeloma.

Experimental Design: We treated ARD, ARP, and MM1S myeloma cells with various concentrations of telomestatin for 7 days and evaluated for telomerase activity. Myeloma cells were treated with the minimal effective telomestatin concentration for 3–5 weeks. Every 7^th day the fraction of live cells was determined by trypan blue exclusion, aliquots of cells were removed for various molecular assays, and the remaining cells were replated at the same cell number and at the same concentration of telomestatin. Telomere length, apoptosis, and gene expression changes were monitored as described in detail in "Materials and Methods."

Results: Telomestatin treatment led to inhibition of telomerase activity, reduction in telomere length, and apoptotic cell death in ARD, MM1S, and ARP myeloma cells. Gene expression profile after 1 and 7 days of telomestatin treatment revealed 2-fold change in only 6 (0.027%) and 51 (0.23%) of 33,000 genes surveyed, respectively. No changes were seen in expression of genes involved in cell cycle, apoptosis, DNA repair, or recombination.

Conclusions: These results demonstrate that telomestatin exerts its antiproliferative and proapoptotic effects in myeloma cells via inhibition of telomerase and subsequent reduction in telomere length. We conclude that telomerase is an important potential therapeutic target for multiple myeloma therapy, and G-quadruplex interacting agents with specificity for binding to telomeric sequences can be important agents for additional evaluation.

This article has been cited by other articles:

				M. A. Shammas, A. Qazi, R. B. Batchu, R. C. Bertheau, J. Y.Y. Wong, M. Y. Rao, M. Prasad, D. Chanda, S. Ponnazhagan, K. C. Anderson, et al. Telomere Maintenance in Laser Capture Microdissection-Purified Barrett's Adenocarcinoma Cells and Effect of Telomerase Inhibition In vivo Clin. Cancer Res., August 1, 2008; 14(15): 4971 - 4980. [Abstract] [Full Text] [PDF]

				D. Sun and L. H Hurley Telomestatin as a Structural Probe for Targeting G-quadruplexes in Telomeric and Promoter Regions Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 315 - 318. [Abstract] [Full Text] [PDF]

				M. A. Shammas, P. Neri, H. Koley, R. B. Batchu, R. C. Bertheau, V. Munshi, R. Prabhala, M. Fulciniti, Y. t. Tai, S. P. Treon, et al. Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications Blood, October 15, 2006; 108(8): 2804 - 2810. [Abstract] [Full Text] [PDF]

				T. Hideshima, D. Chauhan, P. Richardson, and K. C. Anderson Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma J. Clin. Oncol., September 10, 2005; 23(26): 6345 - 6350. [Abstract] [Full Text] [PDF]

				C. Douarre, D. Gomez, H. Morjani, J.-M. Zahm, M.-F. O'Donohue, L. Eddabra, P. Mailliet, J.-F. Riou, and C. Trentesaux Overexpression of Bcl-2 is associated with apoptotic resistance to the G-quadruplex ligand 12459 but is not sufficient to confer resistance to long-term senescence Nucleic Acids Res., April 14, 2005; 33(7): 2192 - 2203. [Abstract] [Full Text] [PDF]

				I. N. Rujan, J. C. Meleney, and P. H. Bolton Vertebrate telomere repeat DNAs favor external loop propeller quadruplex structures in the presence of high concentrations of potassium Nucleic Acids Res., April 7, 2005; 33(6): 2022 - 2031. [Abstract] [Full Text] [PDF]

				A. M. Burger, F. Dai, C. M. Schultes, A. P. Reszka, M. J. Moore, J. A. Double, and S. Neidle The G-Quadruplex-Interactive Molecule BRACO-19 Inhibits Tumor Growth, Consistent with Telomere Targeting and Interference with Telomerase Function Cancer Res., February 15, 2005; 65(4): 1489 - 1496. [Abstract] [Full Text] [PDF]

				D. Gomez, R. Paterski, T. Lemarteleur, K. Shin-ya, J.-L. Mergny, and J.-F. Riou Interaction of Telomestatin with the Telomeric Single-strand Overhang J. Biol. Chem., October 1, 2004; 279(40): 41487 - 41494. [Abstract] [Full Text] [PDF]